YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy

Hu, Jian; Qiu, Dongxu; Yu, Anze; Hu, Jiao; Deng, Hao; Li, Huihuang; Yi, Zhenglin; Chen, Jinbo; Zu, Xiongbing

doi:10.3389/fonc.2021.607224

Cited by 70 publications

(48 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have demonstrated that tumor mutational burden (TMB), which represents the number of somatic mutations that occur on the coding region of the tumor cell genome, may be a biomarker of sensitivity to immune checkpoint inhibitors ( Campbell et al, 2017 ; Chalmers et al, 2017 ; Hu et al, 2021 ). Microsatellite instability (MSI) refers to the random changes in microsatellites in tumor cells.…”

Section: Resultsmentioning

confidence: 99%

FOXM1/lncRNA TYMSOS/miR-214-3p–Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non–Small Cell Lung Carcinoma

Yuan

Jiang

Tang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Lung cancer is the most common cancer with high mortality. Increasing evidence has demonstrated that nonstructural maintenance of chromosomes condensin I complex subunit G (NCAPG) plays a crucial role in the progression of human cancers. However, the biological function and underlying mechanism of NCAPG in non–small cell lung cancer (NSCLC) are still unclear. Here, we utilized diverse public databases to analyze the expression of NCAPG in pan-cancer. We found that NCAPG was highly expressed in various human cancers, especially in NSCLC. NCAPG expression was significantly positively correlated with poor clinical-pathological features, poor prognosis, tumor mutational burden, DNA microsatellite instability, and immune cell infiltration in NSCLC. In addition, our results showed that depletion of NCAPG significantly inhibited NSCLC cell proliferation, migration, and self-renewal abilities, yet these could be reversed by adding microRNA (miRNA)-214-3p. Knockdown of long noncoding RNA (lncRNA) thymidylate synthetase opposite strand (TYMSOS) also inhibits the NSCLC cell proliferation, migration, and self-renewal abilities. In summary, our findings demonstrated that the crucial roles of the FOXM1/lncRNA-TYMSOS/miRNA-214-3p/NCAPG axis in NSCLC may shed light on how NCAPG may act as a therapeutic target for NSCLC.

show abstract

Section: Resultsmentioning

confidence: 99%

FOXM1/lncRNA TYMSOS/miR-214-3p–Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non–Small Cell Lung Carcinoma

Yuan

Jiang

Tang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…As predictors of the therapeutic efficacy of tumor immunotherapy, antitumor immunity is correlated with MSI in the tumor microenvironment [ 43 ]. We subsequently examined the relationships between MSI and CTHRC1 expression to further investigate whether CTHRC1 affects the immune mechanism and response of the TME.…”

Section: Resultsmentioning

confidence: 99%

Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers

et al. 2021

View full text Add to dashboard Cite

Background The function of collagen triple helix repeat containing 1 (CTHRC1) as an oncogene has been reported in a growing number of publications. Bioinformatics methods represent a beneficial approach to examine the mechanism and function of the CTHRC1 gene in the disease process of cancers from a pan-cancer perspective. Methods In this study, using the online databases UCSC, NCBI, HPA, TIMER2, Oncomine, GEPIA, UALCAN, cBioPortal, COSMIC, MEXPRESS, STRING, CCLE, LinkedOmics, GTEx, TCGA, CGGA, and SangerBox, we focused on the relationship between CTHRC1 and tumorigenesis, progression, methylation, immunity, and prognosis. qPCR was used to detect CTHRC1 expression in glioma tissues and cell lines. Results The pan-cancer analysis showed that CTHRC1 was overexpressed in most tumors, and a significant correlation was observed between CTHRC1 expression and the prognosis of patients with cancer. CTHRC1 genetic alterations occur in diverse tumors and are associated with tumor progression. Levels of CTHRC1 promoter methylation were decreased in most cancer tissues compared with normal tissues. In addition, CTHRC1 coordinated the activity of ICP genes through diverse signal transduction pathways, was also associated with immune cell infiltration and the tumor microenvironment, and potentially represented a promising immunotherapy target. We identified CTHRC1-related genes across cancers using the GEPIA2 tool. The single-gene GO analysis of CTHRC1 across cancers showed that it was involved in some signaling pathways and biological processes, such as the Wnt signaling pathway, cell migration, and positive regulation of protein binding. The expression and function of CTHRC1 were also further verified in glioma tissues and cell lines. Conclusions CTHRC1 is overexpressed in various cancer types and functions as an important oncogene that may promote tumorigenesis and development through different mechanisms. CTHRC1 may represent an important therapeutic target for human cancers.

show abstract

“…Frequent mutations in tumor cells lead to resistance against anti-tumor immunotherapy, indicating a worse prognosis of cancer patients [ 27 ]. To explore the effect of THUMPD1 on immune response in tumor tissues, we evaluated the correlations between THUMPD1 expression and TMB, MSI and neoantigen, which are reportedly prognostic biomarkers of cancer immunotherapy [ 28 , 29 ]. TMB is a quantifiable biomarker that helps reveal the total number of mutations in cancer cells.…”

Section: Resultsmentioning

confidence: 99%

Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy

Liu

Yang

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

Background: THUMPD1 is a specific RNA adaptor that assists acetylation of mRNA and production of N4-acetylcytidine (ac4C). However, it remains unclear whether THUMPD1 plays a part in tumorigenesis and therapeutic efficacy. Here, we analyzed the expression profiles and prognostic value of THUMPD1 in pan-cancer and gained insights into the correlation between THUMPD1 expression level and immunotherapy efficacy. Methods: Gene expression pattern and its correlation with prognosis, immune cell infiltration in pan-cancer were obtained from GTEx, CCLE and TCGA databases, with Kaplan-Meier method and Spearman correlation analysis used. Western blotting and immunofluorescence on clinical samples was performed to validate our database-derived results. Correlation between THUMPD1 expression level and immunotherapy responses was also explored, based on clinical cohorts receiving PD-L1 antibody therapy. Finally, GSEA was performed to show the possible tumorigenic mechanism. Results: THUMPD1 was highly expressed in most cancer types, and this elevated expression indicated poor or improved prognosis for different cancers. In kidney renal clear cell carcinoma (KIRC) and rectum adenocarcinoma (READ), patients with higher THUMPD1 expression exhibited a better prognosis, while liver hepatocellular carcinoma (LIHC) patients had worse prognosis. Besides, THUMPD1 was significantly associated with immune cell infiltration, tumor mutation burden (TMB), microsatellite instability (MSI)，immune checkpoints and neoantigen in many cancer types. Further, more clinical advantages and therapeutic responses were observed in patients with high THUMPD1 expression. Conclusions: THUMPD1 may serve as a novel predictor to evaluate cancer prognosis and immune therapy efficacy in diverse cancer types.

show abstract

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy

Cited by 70 publications

References 55 publications

FOXM1/lncRNA TYMSOS/miR-214-3p–Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non–Small Cell Lung Carcinoma

FOXM1/lncRNA TYMSOS/miR-214-3p–Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non–Small Cell Lung Carcinoma

Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers

Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy

Contact Info

Product

Resources

About